All In Biotech

Drug Trial Radar · NCT06411249

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

302

Actual

Start

Jun 6, 2024

Primary completion

Jun 29, 2027

Study completion Jul 30, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Belimumab (GSK1550188)Biological

    GSK1550188 will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52Time frame: At Week 52

Locations

104 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Covina, California

  • GSK Investigational Site

    Fontana, California

  • GSK Investigational Site

    Fullerton, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Mission Hills, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Temecula, California

  • GSK Investigational Site

    Tujunga, California

  • GSK Investigational Site

    Van Nuys, California

  • GSK Investigational Site

    Van Nuys, California

  • GSK Investigational Site

    Whittier, California

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Tamarac, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Morton Grove, Illinois

  • GSK Investigational Site

    Rockford, Illinois

  • GSK Investigational Site

    Baton Rouge, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Lansing, Michigan

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Duncansville, Pennsylvania

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Baytown, Texas

  • GSK Investigational Site

    Colleyville, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Katy, Texas

  • GSK Investigational Site

    Plano, Texas

  • GSK Investigational Site

    Danville, Virginia

  • GSK Investigational Site

    Glendale, Wisconsin

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.